The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities
Standard
The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities. / Worm, Marie ; Köhler, Elodie C. ; Panda, Rachita; Long, Andy; Butler, Lynn M; Stavrou, Evi X; Nickel, Katrin F; Fuchs, Tobias A; Renné, Thomas.
In: J TRANSL MED, Vol. 3, No. 17, 10.2015, p. 247.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities
AU - Worm, Marie
AU - Köhler, Elodie C.
AU - Panda, Rachita
AU - Long, Andy
AU - Butler, Lynn M
AU - Stavrou, Evi X
AU - Nickel, Katrin F
AU - Fuchs, Tobias A
AU - Renné, Thomas
PY - 2015/10
Y1 - 2015/10
N2 - The plasma protein factor XII (FXII) is the initiating protease of the procoagulant and proinflammatory contact system. FXII activates both the bradykinin (BK) producing kallikrein-kinin system and the intrinsic pathway of coagulation. Contact with negatively charged surfaces induces auto-activation of zymogen FXII that results in activated FXII (FXIIa). Various in vivo activators of FXII have been identified including heparin, misfolded protein aggregates, nucleic acids and polyphosphate. Murine models have established a central role of FXII in arterial and venous thromboembolic diseases. Despite the central function of FXII in pathologic thrombosis, its deficiency does not impair hemostasis in animals or humans. The selective role of FXIIa in thrombosis, but not hemostasis, offers an exciting novel strategy for safe anticoagulation based on interference with FXIIa. We have generated the recombinant fully human FXIIa-blocking antibody 3F7, which abolished FXIIa enzymatic activity and prevented thrombosis in a cardiopulmonary bypass system in large animals, in the absence of increased therapy-associated bleeding. Furthermore, 3F7 also interfered with BK-driven edema in the severe swelling disorder hereditary angioedema (HAE) type III. Taken together, targeting FXIIa with 3F7 appears to be a promising approach to treat edema disorders and thrombosis.
AB - The plasma protein factor XII (FXII) is the initiating protease of the procoagulant and proinflammatory contact system. FXII activates both the bradykinin (BK) producing kallikrein-kinin system and the intrinsic pathway of coagulation. Contact with negatively charged surfaces induces auto-activation of zymogen FXII that results in activated FXII (FXIIa). Various in vivo activators of FXII have been identified including heparin, misfolded protein aggregates, nucleic acids and polyphosphate. Murine models have established a central role of FXII in arterial and venous thromboembolic diseases. Despite the central function of FXII in pathologic thrombosis, its deficiency does not impair hemostasis in animals or humans. The selective role of FXIIa in thrombosis, but not hemostasis, offers an exciting novel strategy for safe anticoagulation based on interference with FXIIa. We have generated the recombinant fully human FXIIa-blocking antibody 3F7, which abolished FXIIa enzymatic activity and prevented thrombosis in a cardiopulmonary bypass system in large animals, in the absence of increased therapy-associated bleeding. Furthermore, 3F7 also interfered with BK-driven edema in the severe swelling disorder hereditary angioedema (HAE) type III. Taken together, targeting FXIIa with 3F7 appears to be a promising approach to treat edema disorders and thrombosis.
U2 - 10.3978/j.issn.2305-5839.2015.09.07
DO - 10.3978/j.issn.2305-5839.2015.09.07
M3 - SCORING: Journal article
C2 - 26605293
VL - 3
SP - 247
JO - J TRANSL MED
JF - J TRANSL MED
SN - 1479-5876
IS - 17
ER -
